CoChat

Phase 2b Study of the Clinical Efficacy and Safety of Collagenase Clostridium Histolyticum in Patients With Peyronie Disease

Gelbard, Martin, Lipshultz, Larry I., Tursi, James, Smith, Ted, Kaufman, Greg, Levine, Laurence A. · 2012 · Journal of Urology
Cited by 130

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

PURPOSE: Collagenase Clostridium histolyticum is an investigational nonsurgical treatment for Peyronie disease. In this phase 2b, double-blind, randomized, placebo controlled study we determined the safety and efficacy of collagenase C. histolyticum and assessed a patient reported outcome questionnaire. MATERIALS AND METHODS: A total of 147 subjects were randomized into 4 groups to receive collagenase C. histolyticum or placebo (3:1) with or without penile plaque modeling (1:1). Per treatment cycle 2 injections of collagenase C. histolyticum (0.58 mg) were given 24 to 72 hours apart. Subjects received up to 3 cycles at 6-week intervals. When designated, investigator modeling was done 24 to 72 hours after the second injection of each cycle. We evaluated penile curvature by goniometer measurement, patient reported outcomes and adverse event profiles. RESULTS: After collagenase C. histolyticum treatment significant improvements in penile curvature (29.7% vs 11.0%, p=0.001) and patient reported outcome symptom bother scores (p=0.05) were observed compared to placebo. In modeled subjects 32.4% improvement in penile curvature was observed in those on collagenase C. histolyticum compared to 2.5% worsening of curvature in those on placebo (p<0.001). Those treated with collagenase C. histolyticum who underwent modeling also showed improved Peyronie disease symptom bother scores (p=0.004). In subjects without modeling there were minimal differences between the active and placebo cohorts. Most adverse events in the collagenase C. histolyticum group occurred at the injection site and were mild or moderate in severity. No treatment related serious adverse events were reported. CONCLUSIONS: Collagenase C. histolyticum treatment was well tolerated. We noted significant improvement in penile curvature and patient reported outcome symptom bother scores, suggesting that this may be a safe, nonsurgical alternative for Peyronie disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.juro.2012.01.032

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 19

  1. Taylor, 2007, Peyronie's disease, Urol Clin North Am, 34, 517, 10.1016/j.ucl.2007.08.017 · DOI
  2. Smith, 2008, Peyronie's disease: a critical appraisal of current diagnosis and treatment, Int J Impot Res, 20, 445, 10.1038/ijir.2008.30 · DOI
  3. Sasso, 2007, Peyronie's disease: lights and shadows, Urol Int, 78, 1, 10.1159/000096927 · DOI
  4. El-Sakka, 2008, Conservative treatment for Peyronie's disease: an update, Expert Opin Pharmacother, 9, 53, 10.1517/14656566.9.1.53 · DOI
  5. Hellstrom, 2009, Medical management of Peyronie's disease, J Andol, 30, 397, 10.2164/jandrol.108.006221 · DOI · Paper page
  6. Russell, 2007, Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease, Eur Urol, 51, 640, 10.1016/j.eururo.2006.10.042 · DOI
  7. Chung, 2010, Five-year follow-up of Peyronie's graft surgery: outcomes and patient satisfaction, J Sex Med, 8, 594, 10.1111/j.1743-6109.2010.02102.x · DOI · Paper page
  8. Benson, 2009, Penile shortening after radical prostatectomy and Peyronie's surgery, Curr Urol Rep, 10, 468, 10.1007/s11934-009-0074-z · DOI
  9. Taylor, 2008, Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up, J Sex Med, 5, 2221, 10.1111/j.1743-6109.2008.00941.x · DOI · Paper page
  10. Gelbard, 1993, Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study, J Urol, 149, 56, 10.1016/S0022-5347(17)35998-0 · DOI · Paper page
  11. Gelbard, 1982, Collagenase for Peyronie's disease experimental studies, Urol Res, 10, 135, 10.1007/BF00255956 · DOI
  12. Jordan, 2008, The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study, J Sex Med, 5, 180, 10.1111/j.1743-6109.2007.00651.x · DOI · Paper page
  13. Gelbard, 1985, The use of collagenase in the treatment of Peyronie's disease, J Urol, 134, 280, 10.1016/S0022-5347(17)47123-0 · DOI · Paper page
  14. Hurst, 2009, Injectable collagenase clostridium histolyticum for Dupuytren's contracture, N Engl J Med, 361, 968, 10.1056/NEJMoa0810866 · DOI · Paper page
  15. Gilpin, 2010, Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease, J Hand Surg Am, 35A, 2027, 10.1016/j.jhsa.2010.08.007 · DOI · Paper page
  16. Ralph, 2010, The management of Peyronie's disease: evidence-based 2010 guidelines, J Sex Med, 7, 2359, 10.1111/j.1743-6109.2010.01850.x · DOI · Paper page
  17. Gur, 2011, Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options, Expert Opin Pharmacother, 12, 931, 10.1517/14656566.2011.544252 · DOI · Paper page
  18. Kadioglu, 2002, A retrospective review of 307 men with Peyronie's disease, J Urol, 168, 1075, 10.1016/S0022-5347(05)64578-8 · DOI · Paper page
  19. Gelbard, 1990, The natural history of Peyronie's disease, J Urol, 144, 1376, 10.1016/S0022-5347(17)39746-X · DOI · Paper page

Cited by

See all 130

Metadata

Authors
Gelbard, M., Lipshultz, L. I., Tursi, J., Smith, T., Kaufman, G., & Levine, L. A.
Venue
Journal of Urology
Published
2012-06
Volume
187
Issue
6
Pages
2268-2274
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W1975895485
Cited by
130
References
5
FWCI
9.36
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2b Study of the Clinical Efficacy and Safety of Collagenase Clostridium Histolyticum in Patients With Peyronie Disease. https://app.cochat.ai/papers/10.1016/j.juro.2012.01.032
The paper
Gelbard, M., Lipshultz, L. I., Tursi, J., Smith, T., Kaufman, G., & Levine, L. A. (2012). Phase 2b Study of the Clinical Efficacy and Safety of Collagenase Clostridium Histolyticum in Patients With Peyronie Disease. Journal of Urology. https://doi.org/10.1016/j.juro.2012.01.032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.